Paper Details

  1. Home
  2. Paper Details

Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration?

Author: FungAnne E, HillLauren F, MillerDaniel M, PatelYogin, RosenfeldPhilip J

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

The study explored the impact of macular hemorrhage on visual outcomes in patients with neovascular age-related macular degeneration (nAMD) treated with OCT-guided pro re nata (PRN) ranibizumab. The research investigated whether the presence of hemorrhage without detectable fluid on OCT influenced visual outcomes, providing insights into the role of hemorrhage in treatment decisions.
Paper Details　
Original Abstract of the Article :
To determine whether presence of macular hemorrhage on dilated fundus examination (DFE) or fundus photography influences vision outcomes with OCT-guided pro re nata (PRN) ranibizumab retreatment in patients with neovascular age-related macular degeneration (nAMD), we investigated whether hemorrhage ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.oret.2019.09.006

データ提供：米国国立医学図書館（NLM）

OCT-Guided Retreatment for Exudative Age-Related Macular Degeneration: A Closer Look

Optical coherence tomography (OCT)-guided pro re nata (PRN) ranibizumab retreatment is a common approach for managing exudative age-related macular degeneration (nAMD). This study investigates whether the presence of macular hemorrhage on dilated fundus examination (DFE) or fundus photography influences vision outcomes in patients undergoing OCT-guided PRN retreatment.

The Importance of OCT in nAMD Management

This study, like a camel navigating the shifting sands of nAMD treatment, emphasizes the crucial role of OCT in monitoring disease progression and guiding treatment decisions. The findings suggest that OCT-guided retreatment, combined with careful assessment of macular hemorrhage, may optimize patient outcomes.

Optimizing nAMD Management: A Multifaceted Approach

The study's findings, like a valuable oasis in the desert of nAMD research, highlight the importance of a comprehensive approach to managing the condition. OCT-guided retreatment, combined with careful observation of macular hemorrhage, offers a valuable tool for optimizing treatment strategies and improving patient outcomes.

Dr.Camel's Conclusion

This study underscores the importance of a multi-pronged approach to managing exudative age-related macular degeneration. OCT-guided retreatment, combined with careful assessment of macular hemorrhage, offers a valuable tool for optimizing treatment strategies and maximizing patient outcomes. Like a camel navigating a vast desert, clinicians must be adaptable and utilize all available tools to navigate the challenges of managing this complex condition.

Date :
  1. Date Completed 2021-05-19
  2. Date Revised 2021-05-19
Further Info :

Pubmed ID

31735634

DOI: Digital Object Identifier

10.1016/j.oret.2019.09.006

Related Literature

Article Analysis
・Effective treatment of macular degeneration
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.